Bausch & Lomb Corp

BLCO

Company Profile

  • Business description

    Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

  • Contact

    520 Applewood Crescent
    VaughanONL4K 4B4
    CAN

    T: +1 905 695-7700

    https://www.bausch.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    13,000

Stocks News & Analysis

stocks

Nvidia earnings: Another stellar quarter with no signs of a slowdown

Nvidia remains at the heart of the AI ecosystem.
stocks

Chart of the Week: Software selloff creates opportunity for these two stocks

Can AI disrupt the software business model?
stocks

Market is misinterpreting AI impact on cheap ASX share

Unwarranted sell-off with shares down by half in three months.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,408.7027.40-0.29%
CAC 408,602.3143.240.51%
DAX 4025,146.2029.74-0.12%
Dow JONES (US)49,482.15307.650.63%
FTSE 10010,813.787.370.07%
HKSE26,381.02384.70-1.44%
NASDAQ23,152.08288.391.26%
Nikkei 22558,753.39170.270.29%
NZX 50 Index13,670.71145.131.07%
S&P 5006,946.1356.060.81%
S&P/ASX 2009,175.3027.60-0.30%
SSE Composite Index4,146.630.60-0.01%

Market Movers